Erythromycin has an established role in the treatment of pneumonia due to Mycoplasma pneumoniae and Legionella pneumophila. Its use in acute Q fever pneumonia is not established; indeed, erythromycin has been recorded as having no therapeutic effect on the organism.' We report three patients, all acutely ill with subsequently proved Q fever pneumonia, in whom the use of erythromycin was associated with rapid defervescence and relief of symptoms. The fear that erythromycin, used in non-specific atypical pneumonias, will not be effective against Q fever appears to be less tenable.
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Case reports
Case I-A man aged 44 years. who worked at an abattoir carrying fresh beef carcasses. gave a six-day history of diarrhoea and vomiting, accompanied by myalgic pain, sweats, and rigors. Latterly he had experienced pleuritic chest pain associated with a non-productive cough. On arrival at hospital he was ill and febrile (39°C). The pulse was 100 beats/min and regular; the blood pressure was 140/80 mm Hg. Apart from occasional wheezes examination of the respiratory system showed nothing abnormal. A chest radiograph showed lingular consolidation.
The peripheral white blood count was 5*2 x 10"/1 (79% neutrophils, 18% lymphocytes. 3%n monocytes) and the ESR was 78 mm in the first hour. Samples of sputum and blood sent for culture proved sterile and a stool sample did not show any pathogenic organisms. A diagnosis of atypical pneumonia was made and the man was treated with erythromycin lactobionate intravenously ( I g six hourly). Twenty-four hours after commencing treatment he was apyrexial and felt better (fig). Intravenous treatment was stopped after two days and oral erythromycin estolate (500 mg six hourly) was given for a further seven days. Recovery was rapid but complicated by haemoptysis, and the radiographic changes resolved only slowly. Bronchoscopy was therefore undertaken to exclude a bronchial carcinoma and the result was negative. A combined ventilation-perfusion lung scan showed changes consistent with pulmonary infection only. Serological evidence of acute infection with Coriella biurineti was subsequently found (table). Cases 2 anid3-A married couple. both of whom were in their early forties, had recently returned from a holiday on a farm in Anglesey where there had been calving and lambing. Two weeks later both had experienced severe headache and vomiting. There were no respiratory symptoms. Admission had been precipitated in the wife by signs highly suggestive of meningitis; the 
Discussion
It is doubtful whether the atypical pneumonias can be confidently differentiated on clinical, radiological, biochemical, or haematological grounds.) A clear history of specific exposure may occasionally suggest the aetiological agent. Delay of at least one week is usual, however, before rising serological titres provide the correct diagnosis. In patients with untreated Q fever therefore inappropriate antimicrobial treatment should be a cause for concern as there is a risk of infection in the patient's attendants3 and of chronic Q fever or endocarditis in susceptible patients.4 Coriella biurneti is resistant to erythromycin in vitro and consequently it has been assumed to be ineffective in vivo. Nevertheless, the three patients described, with their rapid recovery from fever and clinical improvement after treatment, provide some evidence for a satisfactory in vivo response to both oral and intravenous erythromycin. There has been one previous 
